-
Je něco špatně v tomto záznamu ?
Evolvability and emergence of tumor heterogeneity as a space-time function
B. Saha, L. Vannucci, B. Saha, P. Tenti, R. Baral
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu úvodníky
- MeSH
- extracelulární matrix MeSH
- lidé MeSH
- nádorové kmenové buňky MeSH
- nádorové mikroprostředí genetika MeSH
- nádory * genetika MeSH
- patologická angiogeneze MeSH
- proliferace buněk genetika MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- úvodníky MeSH
The loss of control of cell proliferation, apoptosis regulation and contact inhibition leads to tumor development. While benign tumors are restricted to their primary space, i.e. where these tumors first originate, the metastatic tumors not only disseminate- facilitated by hypoxia-driven neovascularization- to distant secondary sites but also show substantial changes in metabolism, tissue architectures, gene expression profiles and immune phenotypes. All these alterations result in radio-, chemo- and immune-resistance rendering these metastatic tumor cells refractory to therapy. Since the beginning of the transformation, these factors- which influence each other- are incorporated to the developing and metastasizing tumor. As a result, the complexities in the heterogeneity of tumor progressively increase. This space-time function in the heterogeneity of tumors is generated by various conditions and factors at the genetic as well as microenvironmental levels, for example, endogenous retroviruses, methylation and epigenetic dysregulation that may be etiology-specific, cancer associated inflammation, remodeling of the extracellular matrix and mesenchymal cell shifted functions. On the one hand, these factors may cause de-differentiation of the tumor cells leading to cancer stem cells that contribute to radio-, chemo- and immune-resistance and recurrence of tumors. On the other hand, they may also enhance the heterogeneity under specific microenvironment-driven proliferation. In this editorial, we intend to underline the importance of heterogeneity in cancer progress, its evaluation and its use in correlation with the tumor evolution in a specific patient as a field of research for achieving precise patient-tailored treatments and amelioration of diagnostic (monitoring) tools and prognostic capacity.
Chittaranjan National Cancer Institute Shyamaprasad Mukherjee Road Calcutta 700026 India
Institute of Microbiology Czech Academy of Sciences Videnska 1083 Praha Czech Republic
National Centre for Cell Science Ganeshkhind Pune 411007 India
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22032059
- 003
- CZ-PrNML
- 005
- 20230131150648.0
- 007
- ta
- 008
- 230120s2023 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.cyto.2022.156061 $2 doi
- 035 __
- $a (PubMed)36252436
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Saha, Bhaskar $u National Centre for Cell Science, Ganeshkhind, Pune 411007, India. Electronic address: bhaskar211964@yahoo.com
- 245 10
- $a Evolvability and emergence of tumor heterogeneity as a space-time function / $c B. Saha, L. Vannucci, B. Saha, P. Tenti, R. Baral
- 520 9_
- $a The loss of control of cell proliferation, apoptosis regulation and contact inhibition leads to tumor development. While benign tumors are restricted to their primary space, i.e. where these tumors first originate, the metastatic tumors not only disseminate- facilitated by hypoxia-driven neovascularization- to distant secondary sites but also show substantial changes in metabolism, tissue architectures, gene expression profiles and immune phenotypes. All these alterations result in radio-, chemo- and immune-resistance rendering these metastatic tumor cells refractory to therapy. Since the beginning of the transformation, these factors- which influence each other- are incorporated to the developing and metastasizing tumor. As a result, the complexities in the heterogeneity of tumor progressively increase. This space-time function in the heterogeneity of tumors is generated by various conditions and factors at the genetic as well as microenvironmental levels, for example, endogenous retroviruses, methylation and epigenetic dysregulation that may be etiology-specific, cancer associated inflammation, remodeling of the extracellular matrix and mesenchymal cell shifted functions. On the one hand, these factors may cause de-differentiation of the tumor cells leading to cancer stem cells that contribute to radio-, chemo- and immune-resistance and recurrence of tumors. On the other hand, they may also enhance the heterogeneity under specific microenvironment-driven proliferation. In this editorial, we intend to underline the importance of heterogeneity in cancer progress, its evaluation and its use in correlation with the tumor evolution in a specific patient as a field of research for achieving precise patient-tailored treatments and amelioration of diagnostic (monitoring) tools and prognostic capacity.
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a nádory $x genetika $7 D009369
- 650 _2
- $a patologická angiogeneze $7 D009389
- 650 _2
- $a proliferace buněk $x genetika $7 D049109
- 650 _2
- $a nádorové kmenové buňky $7 D014411
- 650 _2
- $a extracelulární matrix $7 D005109
- 650 _2
- $a nádorové mikroprostředí $x genetika $7 D059016
- 655 _2
- $a úvodníky $7 D016421
- 700 1_
- $a Vannucci, Luca $u Institute of Microbiology, Czech Academy of Sciences, Videnska 1083, Praha, Czech Republic. Electronic address: vannucci@biomed.cas.cz
- 700 1_
- $a Saha, Baibaswata $u Institute of Microbiology, Czech Academy of Sciences, Videnska 1083, Praha, Czech Republic
- 700 1_
- $a Tenti, Paolo $u Institute of Microbiology, Czech Academy of Sciences, Videnska 1083, Praha, Czech Republic
- 700 1_
- $a Baral, Rathindranath $u Chittaranjan National Cancer Institute, Shyamaprasad Mukherjee Road, Calcutta 700026, India. Electronic address: baralrathin@hotmail.com
- 773 0_
- $w MED00001313 $t Cytokine $x 1096-0023 $g Roč. 161, č. - (2023), s. 156061
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/36252436 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20230120 $b ABA008
- 991 __
- $a 20230131150644 $b ABA008
- 999 __
- $a ok $b bmc $g 1891061 $s 1183394
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2023 $b 161 $c - $d 156061 $e 20221015 $i 1096-0023 $m Cytokine (Philadelphia, Pa. Print) $n Cytokine $x MED00001313
- LZP __
- $a Pubmed-20230120